STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure.

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

• Authors: Valentina Cannone, Mark Ledwidge, Chris Watson, Paul M McKie, John C Burnett Jr, Kenneth McDonald
• Journal: JACC. Basic to translational science (JACC Basic Transl Sci) Vol. 6 Issue 6 Pg. 497-504 (Jun 2021) ISSN: 2452-302X [Electronic] United States
• PMID: 34222720 (Publication Type: Journal Article)
• Copyright: © 2021 The Authors.